 AstraZenecas revenue was 10,771 million in the 2nd quarter of 2022, showing a 31 increase from the previous year. Over the past three quarters, a slew of AstraZenecas medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintaining upward pressure on the companys share price. 